|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's Range||107.02 - 108.64|
|52 Week Range||79.11 - 121.53|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||29.05|
|Earnings Date||Oct 28, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||5.20 (4.86%)|
|Ex-Dividend Date||Oct 14, 2021|
|1y Target Est||127.01|
In the latest trading session, AbbVie (ABBV) closed at $107.72, marking a +0.61% move from the previous day.
From texting mishaps to lost reading glasses, the impact of age-related blurry near vision, or difficulty seeing things up close, on daily life can be pervasive. People who struggle with this may have presbyopia, which affects most adults over 40. It's a common and progressive eye condition that reduces the eye's ability to focus on things up close and can create a lot of frustration for those experiencing it.
AbbVie recently announced a strategic partnership with Regenxbio for wet age-related macular degeneration and diabetic retinopathy treatment.